Journal of Clinical Endocrinology & Metabolism, Vol 63, 639-643, Copyright © 1986 by Endocrine Society

ARTICLES

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome

X Bertagna, C Bertagna, MH Laudat, JM Husson, F Girard and JP Luton

RU 486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-(prop-1- ynyl)estra-4,9-dien-3-one] is a steroid analog which antagonizes glucocorticoid action at the receptor level. The pituitary-adrenal response to RU 486 was evaluated in patients with Cushing's syndrome. The acute administration of 400 mg RU 486 at 0800 h in five patients with Cushing's disease induced no significant change in plasma cortisol during the next 10 h compared with the administration of placebo. However, prolonged administration (400 mg daily for 3 days) caused activation of the pituitary-adrenal axis; urinary cortisol increased the most from 727 to 5720, 830 to 8200, 610 to 1020, 110 to 570, and 300 to 990 micrograms/day. Plasma cortisol and lipotropins increased to a lesser extent. Hormone changes appeared on the second day of drug administration and lasted up to 3-4 days after the drug was discontinued. In two patients with nonpituitary-dependent Cushing's syndrome, RU 486 induced no significant change in steroid secretion. We conclude that RU 486 induced a delayed and prolonged pituitary-adrenal response in Cushing's disease; whether the resulting cortisol overproduction will overcome the peripheral effect of RU 486 remains to be determined.

This article has been cited by other articles:

				S. Johanssen and B. Allolio Mifepristone (RU 486) in Cushing's syndrome Eur. J. Endocrinol., November 1, 2007; 157(5): 561 - 569. [Abstract] [Full Text] [PDF]

				J. N. Miner, C. Tyree, J. Hu, E. Berger, K. Marschke, M. Nakane, M. J. Coghlan, D. Clemm, B. Lane, and J. Rosen A Nonsteroidal Glucocorticoid Receptor Antagonist Mol. Endocrinol., January 1, 2003; 17(1): 117 - 127. [Abstract] [Full Text] [PDF]

				D. MORRIS and A. GROSSMAN The Medical Management of Cushing's Syndrome Ann. N.Y. Acad. Sci., September 1, 2002; 970(1): 119 - 133. [Abstract] [Full Text] [PDF]

				J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486) J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3568 - 3573. [Abstract] [Full Text] [PDF]

				G. Wu, N. E. Flynn, and D. A. Knabe Enhanced intestinal synthesis of polyamines from proline in cortisol-treated piglets Am J Physiol Endocrinol Metab, August 1, 2000; 279(2): E395 - E402. [Abstract] [Full Text] [PDF]

				G. Wu, N. E. Flynn, D. A. Knabe, and L. A. Jaeger A cortisol surge mediates the enhanced polyamine synthesis in porcine enterocytes during weaning Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2000; 279(2): R554 - R559. [Abstract] [Full Text] [PDF]

				K. Wiedemann, C. J. Lauer, M. Hirschmann, K. Knaudt, and F. Holsboer Sleep-endocrine effects of mifepristone and megestrol acetate in healthy men Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E139 - E145. [Abstract] [Full Text] [PDF]

				N. E. Flynn and G. Wu Glucocorticoids Play an Important Role in Mediating the Enhanced Metabolism of Arginine and Glutamine in Enterocytes of Postweaning Pigs J. Nutr., May 1, 1997; 127(5): 732 - 737. [Abstract] [Full Text] [PDF]

				D. N. Orth Cushing's Syndrome N. Engl. J. Med., March 23, 1995; 332(12): 791 - 803. [Full Text] [PDF]